Shares of Divi’s Laboratories fell nearly 3% on February 12 after the company reported Q3FY26 earnings that missed revenue and profit expectations, despite better-than-expected operating margins. The stock touched an intraday low of ₹6,201.5 and was trading at ₹6,222.5, down 2.6% on the NSE.
The pharma major posted a consolidated PAT of ₹583 crore, slightly lower than ₹589 crore a year ago, while total income rose 12% year-on-year to ₹2,692 crore. Ebitda grew 19.8% to ₹890 crore, with margins expanding to 34.2%. The company also reported an exceptional loss of ₹74 crore due to new labour codes.
Brokerages remain divided. JM Financial retained a ‘Buy’ citing strong CDMO growth and multiple triggers, while MOFSL maintained ‘Neutral’ due to limited upside at current valuations. Elara Capital reiterated a ‘Sell’, flagging elevated valuations despite steady operational performance.
